Summary
Corteva, Inc. reported strong performance in 2022 with an 11% increase in net sales, reaching $17.5 billion, driven by robust price execution and volume growth across all regions. The company's Seed segment saw a 7% sales increase, primarily due to price hikes, while the Crop Protection segment experienced a significant 17% sales jump, fueled by both price increases and volume growth, particularly from new product introductions. Despite facing headwinds from unfavorable currency impacts and rising input costs, Corteva demonstrated effective cost management and productivity actions, leading to an improvement in Operating EBITDA by 25% to $3.2 billion. The company also returned approximately $1.4 billion to shareholders through share repurchases and dividends. Looking ahead to 2023, Corteva anticipates continued growth, projecting net sales between $18.1 billion and $18.4 billion and Operating EBITDA between $3.4 billion and $3.6 billion, signaling confidence in its strategic priorities and market position.
Financial Highlights
54 data points| Revenue | $17.45B |
| Cost of Revenue | $10.44B |
| Gross Profit | $7.02B |
| R&D Expenses | $1.22B |
| SG&A Expenses | $3.17B |
| Net Income | $1.15B |
| EPS (Basic) | $1.59 |
| EPS (Diluted) | $1.58 |
| Shares Outstanding (Basic) | 720.80M |
| Shares Outstanding (Diluted) | 724.50M |
Key Highlights
- 1Corteva reported a significant 11% increase in net sales for 2022, reaching $17.5 billion, driven by strong price execution (10% increase) and volume gains (5% increase).
- 2The Crop Protection segment was a strong performer, with net sales increasing by 17% year-over-year, driven by price (11%) and volume (9%) growth, supported by new product penetration.
- 3The Seed segment also showed positive momentum, with net sales up 7%, primarily due to a 9% price increase, with strong adoption of its Enlist E3™ soybean trait reaching over 45% of North American acres.
- 4Operating EBITDA saw a substantial increase of 25% to $3.2 billion, reflecting effective cost and productivity actions that offset inflationary pressures and currency headwinds.
- 5Corteva returned approximately $1.4 billion to shareholders in 2022 through share repurchases ($1 billion under the $2 billion program) and dividends ($0.58 per share for the year).
- 6The company announced its intent to acquire Stoller and Symborg for $1.6 billion, expected to close in H1 2023, to bolster its biologicals portfolio.
- 7Corteva provided a positive 2023 outlook, forecasting net sales between $18.1 billion and $18.4 billion and Operating EBITDA between $3.4 billion and $3.6 billion.